Endpoint Health, a therapeutics company, agreed to acquire Iconic Therapeutics, a health care company. Financial terms were not disclosed. "Using our precision AI platform, we could see the great potential for tissue factor, not only as a therapeutic target, but as an opportunity to develop a highly differentiated precision therapy across a wide range of indications where patients have significant unmet medical need. The opportunity to bring the incredible work of the Iconic Therapeutics team into the clinic for autoimmune diseases represents a key step towards our mission of getting the best therapy to each patient, based on their specific biological need," Jason Springs, Endpoint Health CEO and Co-Founder.